Physician profile
Allyson Hebert
NPI 1043936602
$1,422.82
in general payments reported to CMS, 2019-2025
15 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $724 · 2024: $223 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $291.51 | 2022-2025 | Dupixent |
| Genzyme Corporation | $284.81 | 2022-2025 | |
| Glaxosmithkline, LLC. | $267.42 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $99.91 | 2023-2024 | |
| Kaleo, INC. | $92.28 | 2022-2023 | Auvi-Q |
| Octapharma USA, INC. | $68.99 | 2022-2023 | Cutaquig |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Inspire Medical Systems, INC. | $48.38 | 2023-2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $48.04 | 2023-2024 | |
| Hikma Pharmaceuticals USA | $40.98 | 2023-2024 | Ryaltris |
| Abbott Laboratories | $33.87 | 2023 | Freestyle Libre 3 |
| Aytu Biopharma, INC. | $33.09 | 2024-2025 | Karbinal |
| Amgen INC. | $18.30 | 2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $15.01 | 2023 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $12.97 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.